Daa Pangenotypic Epclusa denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issued a Duplicate-Therapy Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) is a pangenotypic direct-acting antiviral (DAA) used to treat chronic hepatitis C across all major genotypes. Humana may issue a duplicate-therapy denial when its utilization-management system detects that another DAA or hepatitis C antiviral has recently been dispensed, is on file as an active prescription, or was approved under a separate benefit. The insurer's logic is that two overlapping treatments address the same clinical problem simultaneously.

This denial is routinely appealable. Pangenotypic DAAs are not interchangeable with every other hepatitis C regimen — genotype, cirrhosis status, prior treatment history, and resistance-associated substitutions all influence which agent is most appropriate. A prescriber can document exactly why Epclusa is the correct therapy rather than a redundant one.

## Federal Appeal Framework

• ACA Section 2719 / external review: If your plan is non-grandfathered, you have the right to an independent external review by an accredited IRO after exhausting internal appeals. The standard window is approximately four months from the denial notice; check your Explanation of Benefits for the exact deadline. An expedited external review (typically 72 hours) is available when your condition is urgent.
• ERISA Section 503: If your plan is employer-sponsored, ERISA requires a full-and-fair review of every adverse benefit determination, including access to the criteria used and the right to submit rebuttal evidence.

## Concrete Appeal Steps and Timeline

1. Request Humana's written denial letter specifying the duplicate-therapy rationale and the exact criteria applied. 2. Obtain a copy of Humana's current hepatitis C or DAA coverage/medical policy from their provider portal or member services. 3. File a Level 1 internal appeal, typically within 180 days of the denial (verify your plan's deadline). 4. If the internal appeal is upheld, request external review within the timeframe stated on the denial notice.

## Documentation to Gather

• Diagnosis confirmation: Current hepatitis C genotype result, viral load, and liver fibrosis/cirrhosis staging from the chart.
• Prior treatment history: Names, dates, and outcomes of any prior DAAs or interferon-based regimens — establish that no other active regimen is currently prescribed.
• Clinical severity: Chart notes documenting fibrosis stage, hepatic function, and any comorbidities affecting treatment selection.
• Prescriber medical-necessity letter: A letter from the treating provider explaining why Epclusa is not duplicative — for example, that no other DAA is active, that a prior agent was stopped, or that a resistance pattern makes Epclusa the appropriate pangenotypic choice.

## Criteria-Mapping Structure

Pull the exact requirements from (a) the FDA-approved prescribing information for Epclusa and (b) Humana's published hepatitis C/DAA coverage policy. For each requirement listed, identify the corresponding chart entry — lab value, clinical note date, or prescriber attestation — that satisfies it. Present this as a side-by-side table in your appeal letter to make the reviewer's job straightforward.